Ipsen reveals “encouraging” data for BN83495

Ipsen has revealed data from a trial into its first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

The drug has been undergoing testing for the treatment of metastatic breast cancer and so far, four patients being administered the treatment have “remained stable” for at least the last six months, according to professor Charles Coombes of Imperial College, London.

He added that he is confident that BN83495 will emerge as a new hormonal option for the treatment of post-menopausal females suffering from the disease in the future.

Also commenting on the findings, Stephane Thiroloix, executive vice-president of corporate development at Ipsen, stated: “Following this important clinical milestone, we look forward to progressing the global development of BN83495 in this indication and in other selected hormone-dependent cancer indications.”

Meanwhile, earlier this month, Ipsen and Roche revealed that a treatment they have collaborated on – taspoglutide – yielded a positive outcome during a clinical study.